Skip to content
Screener

Rigel Pharmaceuticals RIGL Development Milestones — Revenue recognized

Other product segments

Gross product sales
$75.39M+25.2%
Release Of Share Cost Liability
$39.98M
Discounts and allowances
-$20.47M-23.0%
Delivery of drug supplies, royalties and others
$3.9M-42.6%

Similar metrics at other companies

Moody's logo
MCOTransaction Revenue — Revenue recognized
$901M+28.9%
Moody's logo
MCORecurring Revenue — Revenue recognized
$1.28B+7.1%
Moody's logo
MCOCMBS — Revenue recognized
$25M0.0%
Moody's logo
MCOKYC — Revenue recognized
$121M+13.1%
Moody's logo
MCORMBS — Revenue recognized
$35M+20.7%
Moody's logo
MCOBanking — Revenue recognized
$148M+23.3%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$750.37M+25.0%
Enterprise value$794.27M+44.9%
P/E2.1×-4.1×
P/S2.5×+0.3×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Gross product sales$75,388$60,192
Discounts and allowances(20,465)(16,642)
Total product sales, net54,92343,550
Contract revenues from collaborations:
Milestone revenue3,000
Delivery of drug supplies, royalties and others3,8956,783
Total contract revenues from collaborations3,8959,783
Total revenues$58,818$53,333

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's development milestones — revenue recognized?
Rigel Pharmaceuticals (RIGL) reported development milestones — revenue recognized of $0 in Q1 2026.
How has Rigel Pharmaceuticals's development milestones — revenue recognized changed year-over-year?
Rigel Pharmaceuticals's development milestones — revenue recognized decreased by 100.0% year-over-year, from $3M to $0.
What does development milestones — revenue recognized mean?
This metric represents revenue recognized from the achievement of specific clinical, regulatory, or commercial milestones stipulated in collaboration or licensing agreements. It reflects the successful progression of drug candidates through the development pipeline as defined by contractual obligations with external partners. Fluctuations in this metric indicate the timing and success rate of research and development activities rather than recurring product sales.

Ask your AI about Rigel Pharmaceuticals's development milestones — revenue recognized.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude